ALT
Price
$6.38
Change
+$0.18 (+2.90%)
Updated
Sep 9 closing price
56 days until earnings call
VRCA
Price
$1.91
Change
-$0.00 (-0.00%)
Updated
Sep 6 closing price
59 days until earnings call
Ad is loading...

ALT vs VRCA

Header iconALT vs VRCA Comparison
Open Charts ALT vs VRCABanner chart's image
Altimmune
Price$6.38
Change+$0.18 (+2.90%)
Volume$1.45M
CapitalizationN/A
Verrica Pharmaceuticals
Price$1.91
Change-$0.00 (-0.00%)
Volume$1.29M
CapitalizationN/A
View a ticker or compare two or three
ALT vs VRCA Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ALT vs. VRCA commentary
Sep 10, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a StrongSell and VRCA is a Buy.

COMPARISON
Comparison
Sep 10, 2024
Stock price -- (ALT: $6.38 vs. VRCA: $1.90)
Brand notoriety: ALT and VRCA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 56% vs. VRCA: 65%
Market capitalization -- ALT: $453.08M vs. VRCA: $81.07M
ALT [@Biotechnology] is valued at $453.08M. VRCA’s [@Biotechnology] market capitalization is $81.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $582.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileVRCA’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • VRCA’s FA Score: 0 green, 5 red.
According to our system of comparison, both ALT and VRCA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 2 TA indicator(s) are bullish while VRCA’s TA Score has 3 bullish TA indicator(s).

  • ALT’s TA Score: 2 bullish, 8 bearish.
  • VRCA’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, VRCA is a better buy in the short-term than ALT.

Price Growth

ALT (@Biotechnology) experienced а -4.85% price change this week, while VRCA (@Biotechnology) price change was -19.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.88%. For the same industry, the average monthly price growth was +4.67%, and the average quarterly price growth was -1.38%.

Reported Earning Dates

ALT is expected to report earnings on Nov 05, 2024.

VRCA is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (-0.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($453M) has a higher market cap than VRCA($81.1M). ALT YTD gains are higher at: -43.333 vs. VRCA (-73.907). VRCA has higher annual earnings (EBITDA): -77.18M vs. ALT (-100.91M). ALT has more cash in the bank: 165M vs. VRCA (31.9M). ALT has less debt than VRCA: ALT (1.86M) vs VRCA (46.3M). VRCA has higher revenues than ALT: VRCA (13.9M) vs ALT (409K).
ALTVRCAALT / VRCA
Capitalization453M81.1M559%
EBITDA-100.91M-77.18M131%
Gain YTD-43.333-73.90759%
P/E RatioN/AN/A-
Revenue409K13.9M3%
Total Cash165M31.9M517%
Total Debt1.86M46.3M4%
FUNDAMENTALS RATINGS
ALT vs VRCA: Fundamental Ratings
ALT
VRCA
OUTLOOK RATING
1..100
6650
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
82100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9198
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALT's Valuation (83) in the Miscellaneous Commercial Services industry is in the same range as VRCA (96) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to VRCA’s over the last 12 months.

ALT's Profit vs Risk Rating (82) in the Miscellaneous Commercial Services industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to VRCA’s over the last 12 months.

ALT's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to VRCA’s over the last 12 months.

ALT's Price Growth Rating (91) in the Miscellaneous Commercial Services industry is in the same range as VRCA (98) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to VRCA’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that ALT’s stock grew similarly to VRCA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTVRCA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 6 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Bullish Trend 28 days ago
88%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bullish Trend 4 days ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRCA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KKPNY4.17-0.01
-0.24%
Royal KPN NV
WIMI0.76N/A
-0.54%
WiMi Hologram Cloud
SLNO48.54-1.38
-2.75%
Soleno Therapeutics
SMECF408.49-20.51
-4.78%
SMC Corp
BAND15.91-1.19
-6.96%
Bandwidth

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+2.82%
PLRX - ALT
42%
Loosely correlated
+0.08%
EDIT - ALT
42%
Loosely correlated
-2.23%
VKTX - ALT
42%
Loosely correlated
+1.39%
INZY - ALT
41%
Loosely correlated
+2.91%
KRYS - ALT
41%
Loosely correlated
+2.07%
More

VRCA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with TCBP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then TCBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
-8.17%
TCBP - VRCA
41%
Loosely correlated
+4.67%
SCPX - VRCA
38%
Loosely correlated
+1.81%
DNA - VRCA
34%
Loosely correlated
-7.98%
MLYS - VRCA
30%
Poorly correlated
-5.95%
PBYI - VRCA
29%
Poorly correlated
-2.17%
More